Skip to main content

Oral Ketamine for Depression and Anxiety in Hospice

by: Alex Smith, @alexsmithMD

Journal of Palliative Medicine recently published a nice exploratory open label study of daily oral ketamine for depression and anxiety in hospice patients.  We discussed this paper in our last palliative care fellow's journal club, with the esteemed fellow Dr. Virginia Dzul-Church presiding.

I won't regurgitate the whole article - although Eric Widera just pointed out that one of the take home points of discussing this article is the importance of actually reading the article.  In brief, the wonderful Dr. Scott Irwin recruited 14 hospice patients with depression and anxiety and treated them with 0.5mg/kg of ketamine by mouth daily.  He found a significant reduction in both anxiety (starting at day 3) and depressive symptoms (starting at day 14) with few adverse side effects.

Sounds great, right?

Some points to consider:

  • No placebo.  Without a placebo we can't tell how well this drug would have performed above and beyond the placebo effect.  SSRI antidepressants are effective something like 45% of the time.  Placebo is effective something like 30% of the time.  So you're really talking about a small additional benefit,  ~15%, from the active ingredients.
  • Regression to the mean.  Symptoms have a normal variation.  Depression gets worse, depression gets better.  When do we tend to start medications on patients?  Or notice that they have severe symptoms and consider them for a trial?  When they have severe depression.  And yet, just due to the natural variation in symptoms, we would expect depressive symptoms to decrease over time.    Voila!  It appears the treatment worked.  But by doing nothing, the symptoms would likely have improved.
  • Intention to treat.  The above impressive results on depression and anxiety were for the 8 out of 14 subjects who completed the study.  What happened to the other 6?  4 withdrew after day 14 due to lack of response, and two withdrew due to changes in condition unrelated to the medication (that happens in hospice!).  But if you include the subjects you intended to treat, the results would be much less impressive.
All that said, consider - you have a hospice patient.  The patient is depressed and anxious, and has a short time to live.  You've tried methylphenidate, it didn't work.  Raise your hand if you'd consider trying oral ketamine?

My hand is going up.  

Why?  We don't have many good options for treatment of depression and anxiety on a short time frame.  SSRI's take weeks to work.  IV ketamine has been shown to work for depression but IV isn't great for the hospice setting.  When used for pain, oral ketamine at these doses has relatively few side effects.  And then we have this flawed data suggesting it might work, and isn't too harmful.  

What would you do?

Comments

Anonymous said…
If I were the patient's caregiver, I would request my loved one be given oral ketamine. If I were the patient, I would ask my medical staff to give me the oral ketamine. Hospice is known for compassion and helping people control pain. Anxiety and depression are mental pains that are far reaching regarding one's quality of life. I wholeheartedly give a thumbs up to using this medication.
Bruce Scott said…
I've been itching to give it a go.

I've used subanesthetic dose IV ketamine for treatment of complex regional pain syndrome with very good results. I've used it with mixed results in cancer pain with very high opioid requirements. I've just about got my ducks in a row to start using it in a few patients with sickle cell disease who tend to have extended hospitalizations with their vaso-occlusive crises.

The time I looked at trying to get PO ketamine compounded for me, the price was astonishing. (The Twycross 2nd Ed Hospice and Palliative Care Formulary USA and the San Diego Hospice folks before the fall both suggested that the price should not be so bad.) Nobody wanted to allow for the idea that a patient could mix their own solution up (which is actually what HPCFUSA and SD Hospice recommended), so I dropped it.

I've got two nursing home patients that I've been pondering using it in. Both with chronic pain on large opioid doses (one with suspicion for OIH), both with significant psych issues that I've not been able to get on top of (and are likely exacerbating the pain). I've started to ask around to see if it would be permissible to RX oral ketamine.
Paul McIntyre said…
I think its a stretch to say "iv ketamine has been shown to work for depression", based on single dose studies. I'd also add selection bias & confounders to the critique of this article. Dr. Irwin stresses that this was a proof of concept study now requiring RCT or other methodological approaches, etc. So, no, I am not going to prescribe ketamine for depression. Compassion and good science are not mutually exclusive - quite the contrary. Paul McIntyre, Halifax, NS
Bruce Scott said…
Paul McIntyre expresses concern about whether or not we should really say "IV ketamine has been shown to work for depression".

Is this the trial in question?
http://www.ncbi.nlm.nih.gov/pubmed/23982301

I'd agree with the provisional withholding of opinion that it works if you are doing it based on the study being unreplicated or based on the study having design issues.

It had an "active" placebo control, which I'm not sure is ideal. It is midazolam. I'm not sure whether we should consider this to be blinded from a patient's perspective.

However, the NNT is <3, which is quite robust, and much better than our NNTs for oral agents. Half relapsed a week later. The study isn't so poorly designed that accepted it as a basis for doing your own N-of-1 interventions should be considered cowboy medicine. You might not want to be an early adopter, but I think there is enough initial evidence that use isn't inappropriate.

It may depend on how much access you have to psychiatry specialty care. my access is limited regionally. The specialists I have access to DON'T want to see my palliative care patients (heaven forfend they would ever consider seeing a *gasp* hospice patient). I don't have anybody within 30 miles doing ECTs. The state doesn't like my prescribing pscyhostimulants for depression. It might be wishful thinking (or the cult of the new), but I'm really considering trying use of this agent.
Eric Widera said…
Bruce,

They used an active control in that study because in a previous study in 2006 a major limitation was the individuals knew that they were getting ketamine versus the saline control:

http://www.ncbi.nlm.nih.gov/pubmed/16894061

I also personally like the following review of ketamine for depression:

Biol Psychiatry. 2012 October 1; 72(7): 537–547. doi:10.1016/j.biopsych.2012.05.003.

Eric

Popular posts from this blog

Lost in Translation: Google’s Translation of Palliative Care to ‘Do-Nothing Care’

by: Cynthia X. Pan, MD, FACP, AGSF (@Cxpan5X)

My colleagues often ask me: “Why are Chinese patients so resistant to hospice and palliative care?” “Why are they so unrealistic?” “Don’t they understand that death is part of life?” “Is it true that with Chinese patients you cannot discuss advance directives?”

As a Chinese speaking geriatrician and palliative care physician practicing in Flushing, NY, I have cared for countless Chinese patients with serious illnesses or at end of life.  Invariably, when Chinese patients or families see me, they ask me if I speak Chinese. When I reply “I do” in Mandarin, the relief and instant trust I see on their faces make my day meaningful and worthwhile.

At my hospital, the patient population is about 30% Asian, with the majority of these being Chinese. Most of these patients require language interpretation.  It becomes an interesting challenge and opportunity, as we often need to discuss advance directives, goals of care, and end of life care options…

Elderhood: Podcast with Louise Aronson

In this week's podcast we talk with Louise Aronson MD, MFA, Professor of Geriatrics at UCSF about her new book Elderhood, available for purchase now for delivery on the release date June 11th.

We are one of the first to interview Louise, as she has interviews scheduled with other lesser media outlets to follow (CBS This Morning and Fresh Air with Terry...somebody).

This book is tremendously rich, covering a history of aging/geriatrics, Louise's own journey as a geriatrician facing burnout, aging and death of family of Louise's members, insightful stories of patients, and more.

We focus therefore on the 3 main things we think our listeners and readers will be interested in.

First - why the word "Elder" and "Elderhood" when JAGS/AGS and others recently decided that the preferred terminology was "older adult"?

Second - Robert Butler coined the term ageism in 1969 - where do we see ageism in contemporary writing/thinking?  We focus on Louise's…

Psychedelics: Podcast with Ira Byock

In this week's podcast, we talk with Dr. Ira Byock, a leading palliative care physician, author, and public advocate for improving care through the end of life.

Ira Byock wrote a provocative and compelling paper in the Journal of Pain and Symptom Management titled, "Taking Psychedelics Seriously."

In this podcast we challenge Ira Byock about the use of psychedelics for patients with serious and life-limiting illness.   Guest host Josh Biddle (UCSF Palliative care fellow) asks, "Should clinicians who prescribe psychedelics try them first to understand what their patient's are going through?" The answer is "yes" -- read or listen on for more!

While you're reading, I'll just go over and lick this toad.

-@AlexSmithMD





You can also find us on Youtube!



Listen to GeriPal Podcasts on:
iTunes Google Play MusicSoundcloudStitcher
Transcript
Eric: Welcome to the GeriPal Podcast. This is Eric Widera.

Alex: This is Alex Smith.

Eric: Alex, I spy someone in our …